Rémy L.M. Mostard

Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study

Sofía Ramiro, Rémy L.M. Mostard, César Magro‐Checa et al. · Annals of the Rheumatic Diseases · 2020 · 231 citations · Full text

Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis

Rémy L.M. Mostard, Stefan Vöö, Marinus J.P.G. van Kroonenburgh et al. · Respiratory Medicine · 2011 · 189 citations · Full text

Inflammation, Autoimmune Disease, Immunology +5

Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis

Roel J. Erckens, Rémy L.M. Mostard, Petal A. Wijnen et al. · Graefe s Archive for Clinical and Experimental Ophthalmology · 2011 · 181 citations · Full text

Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial

Catharina C. Moor, Rémy L.M. Mostard, Jan C. Grutters et al. · American Journal of Respiratory and Critical Care Medicine · 2020 · 133 citations · Full text

Severity of pulmonary involvement and 18F-FDG PET activity in sarcoidosis

Rémy L.M. Mostard, Johny Verschakelen, Marinus J.P.G. van Kroonenburgh et al. · Respiratory Medicine · 2012 · 113 citations · Full text

Advanced Lung Disease, Pathology, 18F-fdg Pet Activity +4